VIRAX BIOLABS GROUP LTD (VRAX)

KYG9495L1251 - Common Stock

1.75  -0.14 (-7.41%)

Premarket: 1.76 +0.01 (+0.57%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2022 2023 2024 2025 2026
Revenue
YoY % growth

-100.00%		8.56K156.42K
1,727.34%		8.242M
5,169.15%		13.762M
66.97%
EBITDA
YoY % growth
N/AN/A-6.003M
-2.67%		-1.003M
83.30%		612.5K
161.09%
EBIT
YoY % growth
-1.73M
-170.31%		-5.733M
-231.37%		-6.106M
-6.51%		-1.004M
83.56%		612.5K
161.03%
Operating Margin
N/A-66,971.50%-3,903.66%-12.18%4.45%
EPS
YoY % growth
N/AN/AN/A
-5.56%		-0.06
68.42%		0.04
166.67%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 25
EPS
Q2Q % growth		-0.61
68.42%
Revenue
Q2Q % growth		N/A
EBITDA
Q2Q % growth		N/A
EBIT
Q2Q % growth		N/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q2 2025
Q2Q % growth		 4.95K
-93.53%		%
Q4 2024
Q2Q % growth		 79.92K
2,754.29%		%
Q4 2022
Q2Q % growth
-100.00%		%
Q2 2022
Q2Q % growth
-100.00%		%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A 0% 0%
RevenueN/A N/A 0% 0%